There is one clinical trial.
The SARS-CoV-2 coronavirus pandemic is responsible for more than 180,000 deaths worldwide and
20,000 deaths in France. To date, no treatment or vaccine has been successful.
Povidone-iodine is an antiseptic suitable for use on the skin and mucosa with potent
virucidal activity, particularly against coronaviruses. It is marketed for oro-nasopharyngeal
decolonization.
24 patients with positive nasopharyngeal SARS-CoV-2 carriage will be randomized (1:1) in an
experimental group (benefiting from povidone iodine decolonization) or a control group.
Patients in the experimental group will be asked to gargle with a 1% povidone-iodine
solution, spray their nose with the same antiseptic solution, and finally applied 10%
povidone-iodine cream in each nostril, all four times a day for five days. Patients will be
followed for 7 days to evaluate the efficacy and safety of povidone iodine decolonization.
Primary Outcomes
Measure: Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7 Time: Day 7
Secondary Outcomes
Measure: Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage Time: Day0, Day1, Day3, Day5 and Day7
Measure: Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures Time: Day0, Day1, Day3, Day5 and Day7
Measure: Thyroid tests at Day0 and Day7 Time: Day0 and Day7
Measure: Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort) Time: Day7
Measure: Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea Time: Day0, Day1, Day3, Day5 and Day7
Measure: Need for ward or intensive care hospitalization Time: Day0, Day1, Day3, Day5 and Day7